Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
IMC-3C5 is a monoclonal antibody, which binds FLT4 (VEGFR3) to prevent ligand based activation, which may result in decreased angiogenesis and tumor growth (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|IMC-3C5||LY3022856|LY-3022856||VEGFR3 Antibody 1||IMC-3C5 (LY3022856) is a monoclonal antibody, which binds FLT4 (VEGFR3) to prevent ligand based activation, which may result in decreased angiogenesis and tumor growth (PMID: 27566701).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||IMC-3C5||Phase I||Actionable||In a Phase I trial, 50% (4/8) of colorectal cancer patients experienced a progression free survival when treated with IMC-3C5, however, no responses were reported per RECIST (Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 3530).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|